It should be noted that anti-PSGL-1-treated patient-derived tumor cultures demonstrated anti-tumor immune responses and T-cell activation even in tumors not responding to Pembrolizumab—a high unmet need patient population. The gene discussed is SELPLG; the disease is neoplasm.